Pro-Surfactant Protein B As a Biomarker for Lung Cancer Prediction
Pro-Surfactant Protein B As a Biomarker for Lung Cancer Prediction
复制标题
DOI：
10.1200/jco.2013.50.6105
复制
发表时间：
2013-12-20
影响因子：
45.3
通讯作者：
Taguchi, Ayumu
中科院分区：
文献类型：
--
作者：
Sin, Don D.;Tammemagi, C. Martin;Taguchi, Ayumu
目的 初步研究已确定前表面活性剂蛋白 B (pro-SFTPB) 是一种有前景的非小细胞肺癌血液生物标志物。我们进行了一项研究，以确定 pro-SFTPB 在识别随后被诊断为肺癌的个体方面的独立预测潜力。 患者和方法 使用基线访视时收集的血浆样本，对参加泛加拿大肺癌早期检测研究的 2,485 名个体进行了 Pro-SFTPB 水平测量。除了已知的肺癌危险因素外，还使用多变量逻辑回归模型来评估 pro-SFTPB 的预测能力。评估校准和区分，后者通过受试者工作特征曲线（AUC）下的面积来评估。采用病例对照研究设计，对胡萝卜素和视黄醇功效试验 (CARET) 参与者收集的样本进行了外部验证。结果根据年龄、性别、体重指数、癌症个人史、肺癌家族史、预测的一秒用力呼气量、每天平均吸烟支数和吸烟持续时间进行调整后，pro-SFTPB（对数转换）的比值比为 2.220（95% CI， 1.727 至 2.853；P < .001)。使用和不使用 pro-SFTPB 的完整模型的 AUC 分别为 0.741（95% CI，0.696 至 0.783）和 0.669（95% CI，0.620 至 0.717；AUC 差异 P < .001）。在 CARET 研究中，使用 pro-SFTPB 产生的 AUC 为 0.683（95% CI，0.604 至 0.761）。 结论 血浆中的 Pro-SFTPB 是肺癌的独立预测因子，可能是对现有肺癌风险预测模型的有价值的补充。
Purpose Preliminary studies have identified pro-surfactant protein B (pro-SFTPB) to be a promising blood biomarker for non-small-cell lung cancer. We conducted a study to determine the independent predictive potential of pro-SFTPB in identifying individuals who are subsequently diagnosed with lung cancer.Patients and Methods Pro-SFTPB levels were measured in 2,485 individuals, who enrolled onto the Pan-Canadian Early Detection of Lung Cancer Study by using plasma sample collected at the baseline visit. Multivariable logistic regression models were used to evaluate the predictive ability of pro-SFTPB in addition to known lung cancer risk factors. Calibration and discrimination were evaluated, the latter by an area under the receiver operating characteristic curve (AUC). External validation was performed with samples collected in the Carotene and Retinol Efficacy Trial (CARET) participants using a case-control study design.Results Adjusted for age, sex, body mass index, personal history of cancer, family history of lung cancer, forced expiratory volume in one second percent predicted, average number of cigarettes smoked per day, and smoking duration, pro-SFTPB (log transformed) had an odds ratio of 2.220 (95% CI, 1.727 to 2.853; P < .001). The AUCs of the full model with and without pro-SFTPB were 0.741 (95% CI, 0.696 to 0.783) and 0.669 (95% CI, 0.620 to 0.717; difference in AUC P < .001). In the CARET Study, the use of pro-SFPTB yielded an AUC of 0.683 (95% CI, 0.604 to 0.761).Conclusion Pro-SFTPB in plasma is an independent predictor of lung cancer and may be a valuable addition to existing lung cancer risk prediction models.